ICT-121 specifically targets CD133, a cancer stem cell marker that is overexpressed in a wide variety of solid tumors, including ovarian, pancreatic, and breast cancers.
In June 2017, ImmunoCellular announced the presentation of data from the phase 1 clinical trial of ICT-121 in patients with recurrent glioblastoma. The data from the 20-patient, open-label, multi-center study show that 6 of 20 patients are alive (as of April 2017; survival ranging from 10 to 24 months), and these patients will continue to be followed. As noted in the data presentation, ICT-121 was generally safe and well tolerated. As also noted, although diversity in patient disease severity resulting from a protocol amendment to expand patient eligibility makes interpretation of survival data difficult, the results are encouraging and warrant further investigation. Pending immune response data will provide insight into the potential effectiveness of ICT-121 in inducing the formation of cytotoxic T cells targeting CD133, a cancer stem cell marker.